QURE beat EPS expectations by 33.69%
Mar 02, 2026, 11:35 PM
0.00%
What does QURE do
uniQure NV, headquartered in Amsterdam, specializes in gene therapies and employs 480 staff, focusing on one-time treatments for genetic diseases. Their lead candidates include AMT-061 for hemophilia B and AMT-130 for Huntington's disease.
uniQure N.V. (QURE) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, uniQure N.V.'s actual EPS was -$0.64, beating the estimate of -$0.97 per share, resulting in a 33.69% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.